AMLX
Amylyx Pharmaceuticals, Inc.
$27.20
-4.80%
2026-10-23
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-25.54
EPS (TTM)
$-1.41
ROE
-74.7%
Profit Margin
0.0%
Debt/Equity
2.20
Price/Book
13.73
Beta
-0.12
Market Cap
$3.76B
Avg Volume (10D)
1.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$41.14
60D Low
$19.30
Avg Volume
2.3M
Latest Close
$27.20
Get breakout alerts for AMLX
Sign up for Breakout Scanner to receive daily notifications when AMLX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Amylyx Pharmaceuticals, Inc. (AMLX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AMLX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AMLX operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.